Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.

Schizophrenia research - 1 Sept 2013

Ramsey Timothy L, Liu Qian, Massey Bill W, Brennan Mark D

Abstract excerpt

Pharmacogenetic (PGx) predictors of response would improve outcomes in antipsychotic treatment. Based on both biological rationale and prior evidence of an impact on Parkinson's disease, we conducted an association study for 106 SNPs in the synaptic vesicle protein 2C (SV2C) gene using genetic and treatment response data from the Clinical Trial of Antipsychotic Intervention Effectiveness (CATIE). We examined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Linkage Disequilibrium
Share to Membrane Glycoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nerve Tissue Proteins

Share to Pharmacogenetics

Share to Psychiatric Status Rating Scales

Share to Schizophrenia

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23886675
DOI: 10.1016/j.schres.2013.07.008
PMCID: PMC3845218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.PMID 23886675Read ↗

Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study.Semantic proximity Read ↗

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.Semantic proximity Read ↗

Pharmacogenetics-Guided Advances in Antipsychotic Treatment.Semantic proximity Read ↗

The pharmacogenetics of antipsychotic treatment.Semantic proximity Read ↗

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Semantic proximity Read ↗

Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia.Semantic proximity Read ↗

Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia.Semantic proximity Read ↗

Association of 5-HTR2A T102C and A-1438G polymorphisms with clinical response to atypical antipsychotic treatment in schizophrenia: A meta-analysis.Semantic proximity Read ↗

Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.Semantic proximity Read ↗

The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients.Semantic proximity Read ↗

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.